Nephros

Nephros Pre-Tax Margin

The Pre-Tax Profit Margin of Nephros (NEPH) as of Nov 5, 2026 is 6.42 %. In the previous year, Pre-Tax Profit Margin was 0.63 % — a change of 921.36% (higher).

Pre-Tax Margin

6.42 %

YoY

921.36%

Last updated:

Pre-Tax Profit Margin of Nephros is 2025 6.42 % . Pre-Tax Profit Margin of Nephros was 2024 0.63 % . It decreases by 921.36% higher compared to the previous year.

The Nephros Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-60.10 USD
Jan 1, 2019
-32.94 USD
Jan 1, 2020
-52.87 USD
Jan 1, 2021
-27.25 USD
Jan 1, 2022
-42.88 USD
Jan 1, 2023
-11.06 USD
Jan 1, 2024
0.63 USD
Jan 1, 2025
6.42 USD
The Nephros Pre-Tax Margin history
YEARPre-Tax MarginYoY
6.42 %+921.36%
0.63 %-105.68%
-11.06 %-74.20%
-42.88 %+57.35%
-27.25 %-48.46%
-52.87 %+60.50%
-32.94 %-45.19%
-60.10 %-11.88%
-68.21 %-47.81%
-130.69 %-17.73%
-158.85 %-62.33%
-421.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nephros Stock analysis

What does Nephros do? Nephros, Inc. generates revenue through its Water Filtration and Renal Products segments. The Water Filtration segment sells high-performance water purification filters for hospitals, healthcare facilities, dialysis centers, commercial facilities, military, and outdoor recreation markets. The Renal Products segment offers a second-generation hemodiafiltration system for end-stage renal disease patients. Products include ultrafiltration systems used in medical and commercial applications, with subsidiaries Biocon 1, LLC, Aether Water Systems, LLC, and Specialty Renal Products, Inc. supporting sales and development. The company's water filtration products are sold to hospitals, dialysis centers, and commercial facilities, while the hemodiafiltration system targets healthcare providers treating ESRD patients. Subsidiaries handle specialized development and distribution, ensuring market coverage across medical and commercial sectors. Revenue streams are derived from both segments, with products serving healthcare infrastructure and renal treatment needs. Nephros, Inc. focuses on medical device solutions for renal disease and water purification, leveraging its subsidiaries to expand market reach. The Water Filtration segment serves healthcare and commercial clients, while the Renal Products segment addresses ESRD treatment through advanced hemodiafiltration technology, creating a diversified revenue model. Nephros is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nephros stock

Pre-Tax Profit Margin of Nephros is 6.42 % in 2025.

Pre-Tax Profit Margin of Nephros changed from 0.63 % to 6.42 %, representing a 921.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Nephros since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Nephros with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Nephros

All Key Metrics — Nephros